


Scolersants and Coagulation

Kurosh Parsi


Haematology Research Lab, St Vincent's Hospital, Sydney
University of New South Wales, Sydney





Kurosh Parsi
ACP NZ 2010

Historical view of coagulation

Extrinsic pathway




Intrinsic pathway



Kurosh Parsi
ACP NZ 2010


Cell Based Model

- Now recognized that cells do more than just provide a phospholipid surface
- Cells considered to direct haemostasis



Hoffman M and Monroe DM. *Hematol Oncol Clin N Am* 21 (2007) 1-11.
Kurosh Parsi
ACP NZ 2010

Coagulation Pathways



Kurosh Parsi
ACP NZ 2010

Basic haemostasis





- Haemostasis = balance between 'procoagulant' and 'anticoagulant' forces
- Usually divided into 2 phases:
 - **Primary haemostasis** = formation of platelet plug
 - **Secondary haemostasis** = activation of coagulation cascade

Primary haemostasis

- Platelet plug formation at sites of injury
- Occurs within seconds of injury
- Important in stopping blood loss from capillaries, small arterioles, and venules

Secondary haemostasis

- Reactions of plasma coagulation system that result in **fibrin formation**
- Requires **several minutes** for completion
- Fibrin strands **strengthen** the primary haemostatic plug
- Important in **larger vessels** and
- Prevents bleeding **hours or days** after the injury





Sclero-coagulation Studies

- The effects of STS and POL on:
 - Clotting tests
 - Clotting factors
 - Red cell lysis
 - Platelet lysis
 - Platelet derived microparticles

Kurosh Parsi
 UIP Monaco 2009

Measurement of



- Clotting times
 - Platelet-rich plasma (PRP)
 - Platelet-poor plasma (PPP)
- Haemolysis
 - Whole blood
 - Washed red cells







Kurosh Parsi
 UIP Monaco 2009

Measurement of

- Clotting factors
 - Factor assayed on pooled normal plasma
 - Activity at 100% initially
 - Mixed with 0.3% STS/POL
 - Duration: 5 and 30 minutes
- Platelet lysis
 - Turbidity measurements
- PMP
 - Flow cytometry

Kurosh Parsi
 UIP Monaco 2009





Effect on Clotting Factors

European Journal of Vascular & Endovascular Surgery

Parsi K, Exner T, Connor DE, Ma DD, Joseph JE
In Vitro Effects of Detergent Sclerosants on Coagulation, Platelets and Microparticles
 Eur J Vasc Endovasc Surg. 2007;34:731-40

Kurosh Parsi
 ACP NZ 2010

Effect of Sclerosants on Clotting Factors

FACTOR	PNP with 0.3% POL		PNP with 0.3% STS	
	T = 5 min	T = 30 min	T = 5 min	T = 30 min
II	102%	97%	96%	92%
V	70	59	54	7
X	76	75	90	20
VII	82	79	72	5
VIII	117	106	97	61
IX	111	119	88	31
XI	152	126	90	42
XII	135	135	105	107



Kurosh Parsi
 ACP NZ 2010

Effect on Platelets

European Journal of Vascular & Endovascular Surgery

Parsi K, Exner T, Connor DE, Ma DD, Joseph JE
In Vitro Effects of Detergent Sclerosants on Coagulation, Platelets and Microparticles
 Eur J Vasc Endovasc Surg. 2007;34:731-40

Kurosh Parsi
 ACP NZ 2010




Effect on Platelet Derived Microparticles

European Journal of Vascular & Endovascular Surgery

Parsi K, Exner T, Connor DE, Ma DD, Joseph JE
In Vitro Effects of Detergent Sclerosants on Coagulation, Platelets and Microparticles
 Eur J Vasc Endovasc Surg. 2007;34:731-40


Kurosh Parsi
 ACP NZ 2010



- ### Summary
- High Concentration (>0.6%)
 - STS prolongs all clotting times
 - Possess anticoagulant properties (STS > POL)
 - STS significantly destroyed FV and FVIII
 - Lyse PLT
 - Lyse PMP
 - Low Concentrations (STS 0.1-0.3%)
 - Shortened XACT and SACT
 - Procoagulant properties (POL > STS)
 - Activated PLT
 - Released PDMP

Normal Thrombus Generation


Kurosh Parsi
ACP NZ 2010



- ### Antithrombotic Mechanisms
- Help to limit coagulation where it is not required
 - Inactivate specific clotting factors such as:
 - Antithrombin (AT) - FXa and FII
 - Proteins C and S (PC, PS) - FVa and FVIII
 - Tissue factor pathway inhibitor (TFPI) - TF




Antithrombotic Mechanisms

- Therapeutic anticoagulant drugs act via similar mechanisms
 - **Heparin** binds to AT
 - Increases its ability to inactivate **factors X, thrombin**
 - For heparin to work you need AT



Methods

- Freeze dried samples spiked with POL and STS
- PC and AT determined using chromogenic assays
- Free PS determined by immuno-turbidimetric method




Apparent rise in AT

- Compared samples containing 1.5% STS
 - In bovine serum albumin (BSA) VS hydrolysed gelatine (no plasma)
 - BSA fully neutralises STS
- Sample containing BSA displayed no AT
- Sample containing hydrolysed gelatin produced 46% AT activity
- Rise in AT activity due to the direct effect of STS on thrombin used in this assay

Effect on APC induced anticoagulation


- Normal plasma
- POL and STS
- Tested with and without APC present in $CaCl_2$
- APTT measured

STS Effect on APC



Kurosh Parsi
ACP NZ, 2010


POL Effect on APC



Kurosh Parsi
ACP NZ, 2010

Activated PC resistance (APCR)

APC Ratio = clotting time with APC / clotting time without APC



Activated PC resistance (APCR)

APC Ratio > 2 Normal


APC Ratio < 1.8 indicates abnormality

- lack of sensitivity of FV to APC or APC Resistance
- APCR
 - FV Leiden mutation or
 - other factors that reduce the sensitivity of FV to APC eg liver disease or OCP

Activated PC resistance (APCR)

- Normal and APC resistant plasma containing 0.15%-0.25% sclerosants were mixed with APC
- dRVVT-LR based assay was used
- Ratios of clotting times with APC to those without APC were derived:

Effect on APC Resistance




Kurash Parsi
ACP NZ 2010

Comparison with heparin

- Sclerosants at various dilutions were added to normal plasma +/- heparin
- APTT was measured to compare the anticoagulant activity of heparin against activity of sclerosant

Comparison with heparin




Kurash Parsi
ACP NZ 2010


Interaction with Heparin

- Sclerosants added to normal plasma with and without heparin present
- APTT measured

STS Interaction with heparin



Kurash Parsi
ACP NZ 2010



Summary STS High Cn

- **Anti-thrombotic**
 - Destroys factors V and VII
 - Potentiates the effect of APC
 - Mimicks Anti-FII and anti-FXa effect of AT
 - Directly destroys clotting factors
- **Pro-thrombotic**
 - Destroys PC, PS and AT

Net effect
ANTI-THROMBOTIC

Summary POL HIGH Cn

- POL by contrast:
 - Does not demonstrate an inhibitory effect on APC
 - Increases APC resistance
 - Does not inhibit clotting factors *in vitro*

Net effect
Neutral
?/- Pro-thrombotic

Summary STS and POL Low Cn

- **Anti-thrombotic**
 - nil
- **Pro-thrombotic**
 - Activate PLT
 - Release PMP
 - Shortens XACT, SACT

Net effect
PRO-THROMBOTIC

Scleroneutralization

Parsi K, Exner T, Ma DD, Connor DE, Joseph JE, Herbert A
 The Lytic Effects of Detergent Sclerosants on Erythrocytes, Platelets, Endothelial Cells and Microparticles are Attenuated by Albumin and other Plasma Components *in Vitro*
Endovasc Surg. 2008;36:216-223


Kurosh Parsi
ACP NZ 2010

Objectives

- To investigate the *in vitro* effects and interactions of STS and POL on
 - RBC
 - Platelets
 - PMPs
 - Endothelial cells
- Protective effects of plasma components including albumin




Haemolysis

- Sclerosants were added to
 - washed red cells
 - plasma containing sedimented blood cells
- Absorbance measured at 520nm, peak absorption for free Hb released from lysed cells



Sclerosants Neutralized by Albumin

- Mixture of Bovine Serum Albumin (BSA) and sclerosants added to washed red cells
- Absorbance measured at 405nm



Summary

- Haemolysis in plasma was caused by
 - STS > 0.25%
 - POL > 0.45%
- Albumin neutralized haemolysis induced by the sclerosants
- Sclerosants had a similar lytic effect on platelets at high concentrations also inhibited by albumin

Take home message!

1ml of 3% STS will be neutralized by 5mls of blood
 1ml of 3% POL will be neutralized by 2.5ml of blood

Diameter mm	Length cm
14	3.2
8	10
5	25.5
2	159

- Veins fill up from tributaries, deep veins and other veins, which would make these calculation meaningless!!

- Why foam is more potent than liquid!

POL is inhibited more than STS!

POL was more active than STS in both saline and 4% BSA

50% Haemolysis	STS (%)	POL (%)
In saline alone	0.006 (1x)	0.0035 (1x)
In saline + 4% BSA	0.2 (33.3x)	0.1 (28.6x)
In whole blood	0.3 (50x)	0.57 (163x)

Kurash Parsi
ACP NZ 2010

1ml 3% STS Saline 1% STS


1ml 3% STS BSA 0.03% STS
 x33 less than in saline
 x100 less than the original 3%

1ml 3% STS WB 0.02% STS
 x50 less than in saline
 x150 less than 3%

1ml 3% POL Saline 1% POL



1ml 3% POL BSA 0.03% POL
 X30 less than in saline
 X100 less than original 3%

1ml 3% POL WB 0.006% POL
 X163 less than in saline
 X500 less than the original



Platelet microparticle (PMP)

- PMP formation was assessed in response to sclerosants
 - In PRP
 - Washed platelet samples
- Flow cytometry performed using Annexin V and CD41a as markers




Results

- In PRP, STS and POL concentration of 0.2% induced PMP
- In washed platelets, STS and POL concentration of 0.01% induced PMP

Endothelial cell lysis

- HUVECs were cultured to confluence
- Mixtures of sclerosants and BSA were added to HUVECs
- Lysis was determined by absorbance at 540nm



Results

- POL had less lytic effects on endothelial cells
- Both plasma and BSA reduced the lytic effect of STS on the endothelial cells

Conclusion and Summary

- Sclerosants at therapeutic concentrations lyse **BLOOD CELLS** and **ENDOTHELIAL CELLS**
- Both sclerosants induce release of **PMP**
- Albumin significantly inhibits both sclerosants
- POL is more potent than STS if in the absence of plasma components

Conclusion and Summary

- The **LESS ALBUMIN** present the **LESS SCLEROSANT CONCENTRATION**
- **Post-sclerotherapy DVT** is possibly rare due to neutralization of sclerosants by albumin in deep veins



Interaction of detergent sclerosants with the coagulation system: an update

Kurosh Parsi,^{1,2} Thomas Exner,¹ David Ma,^{1,2} and Joanne Joseph^{1,2}

¹ Haematology Research Lab, St Vincent's Hospital, Sydney
² University of New South Wales, Sydney